<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937543</url>
  </required_header>
  <id_info>
    <org_study_id>TRIV001</org_study_id>
    <nct_id>NCT04937543</nct_id>
  </id_info>
  <brief_title>Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19</brief_title>
  <acronym>TRIVID</acronym>
  <official_title>Randomized, Open-label, Three Arms Study to Evaluate the Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources in Patients With ≥ 18 Years Old (TRIVID Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UPECLIN HC FM Botucatu Unesp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the new&#xD;
      coronavirus, causes a disease called COVID-19 that can trigger aggressive inflammatory&#xD;
      responses. In this sense, inhaled corticosteroid therapy (IC) has shown some favorable&#xD;
      results in controlling the worsening of the disease, given that it has effects on pulmonary&#xD;
      inflammation and can be an intervention to be used in the mild manifestations of COVID-19 in&#xD;
      order to prevent disease progression and severity. Regarding the role of bronchodilators,&#xD;
      studies have suggested that their combination with IC exerts synergistic therapeutic effects.&#xD;
      Objective: To determine the efficacy of inhaled therapy of&#xD;
      beclomethasone/formoterol/glycopyrronium (BFG) (100/6/12.5mcg) and/or beclomethasone HFA 250&#xD;
      mcg in preventing the use of healthcare resources in patients ≥ 18 years of age at 28 days&#xD;
      compared to usual care. Method: participants will be randomized according to a ratio of 1:1:1&#xD;
      into three groups: (Group 1) Standard of care + BFG two doses 2x/day; (Group 2) standard&#xD;
      treatment + beclomethasone HFA two doses 2x/day and (Group 3) standard treatment. After&#xD;
      collecting the signed informed consent form, research participants will be treated for 28&#xD;
      days and, after two days, will undergo a spirometry test. Therefore, the total duration of&#xD;
      the study for a given participant will be up to 30 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 28, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in preventing the use of health resources in patients</measure>
    <time_frame>28 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airway obstruction</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small airway obstruction</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>computadorized tomography</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>No intervation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receiving standart of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental intervation one</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving standart of care + inhaled beclometasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental intervation two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled beclametasone</intervention_name>
    <description>Adding belcamethasone to standard of care for Covid 19 positive patients</description>
    <arm_group_label>Experimental intervation one</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inahaled beclomethasone / formoterol / glycopyrronium</intervention_name>
    <description>Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients</description>
    <arm_group_label>Experimental intervation two</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: A research participant will be eligible to participate in this study if&#xD;
        ALL of the following criteria are met:&#xD;
&#xD;
          1. Adult men or women (≥ 18 years of age)&#xD;
&#xD;
          2. PCR positive SarsCoV-2&#xD;
&#xD;
          3. Symptomatic participants must have at least 1 of the following symptoms in the&#xD;
             inclusion: fever or self-reported fever perception in the last 24 hours, headache,&#xD;
             sore throat, dry cough, fatigue, chest pain or choking sensation (without associating&#xD;
             to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with&#xD;
             up to 10 days onset.&#xD;
&#xD;
          4. Participants with arterial pulse oximetry (SpO2) saturation ≥ 92% in room air at&#xD;
             inclusion.&#xD;
&#xD;
          5. Participants with the following hematological and biochemical laboratory parameters&#xD;
             obtained in the period of 7 days before D0:&#xD;
&#xD;
               -  Hemoglobin&gt; 9.0 g / dL-1&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1000 mm-³&#xD;
&#xD;
               -  Platelets ≥ 100,000 mm-3&#xD;
&#xD;
               -  Creatinine clearance ≥ 30 mL / min-1 using the Cockcroft-Gault formula&#xD;
&#xD;
               -  Alkaline phosphatase &lt;10 × upper limit of normal (LSN), AST (TGOS) and ALT (TGPS)&#xD;
                  &lt;10 × LSN.&#xD;
&#xD;
               -  Laboratory pregnancy test (Negative β-hCG).&#xD;
&#xD;
          6. Participants must understand, sign and date the voluntary informed consent form in&#xD;
             writing at the visit prior to any specific protocol procedure.&#xD;
&#xD;
          7. Participants must be able and willing to comply with study visits and procedures, as&#xD;
             per the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Research participants who meet any of the following exclusion criteria will be excluded&#xD;
        from the study:&#xD;
&#xD;
          1. Participants with moderate or severe acute respiratory failure or needing non-invasive&#xD;
             ventilation or oxygen, or with SpO2 &lt;92% or tachypnea (respiratory rate ≥ 30 breaths /&#xD;
             minute).&#xD;
&#xD;
          2. Participants with pre-existing, severe and uncontrolled organ failure, which prevents&#xD;
             participation in the study by the investigator's judgment (non-relevant cardiac&#xD;
             disease)&#xD;
&#xD;
          3. Participant diagnosed with previous asthma using inhaled or oral corticosteroids in&#xD;
             the last four weeks.&#xD;
&#xD;
          4. Participant with previous use, in the last ten days of randomization, of inhaled, oral&#xD;
             or injectable corticosteroids.&#xD;
&#xD;
          5. Participant with previous diagnosis of chronic obstructive pulmonary disease, even if&#xD;
             he is not using any inhaled medication.&#xD;
&#xD;
          6. Pregnant or lactating women.&#xD;
&#xD;
          7. Use of any product under investigation or unregistered within 3 months or within 5&#xD;
             half-lives before baseline, whichever is longer.&#xD;
&#xD;
          8. Hypersensitivity to the drug and / or its excipients.&#xD;
&#xD;
          9. Any condition that, in the investigator's opinion, could compromise the participant's&#xD;
             safety or his adherence to the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suzana Minamoto, Ph.D.</last_name>
    <phone>+55 14 38801663</phone>
    <email>suzana.tanni@unesp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luana Pagan, Ph.D.</last_name>
    <phone>+55 14 38801663</phone>
    <email>luanapagan@alunos.fmb.unesp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <zip>18618687</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Suzana Minamoto, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Suzana Minamoto, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>Bronchodilators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

